Theriva Biologics (TOVX) Operating Expenses (2010 - 2026)

Theriva Biologics (TOVX) has reported Operating Expenses for 17 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 45.05% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $22.1 million (down 13.05% YoY), while the FY2025 annual figure was $24.1 million, down 8.71% from the prior year.
• Operating Expenses improved to $2.4 million in Q1 2026 per TOVX's latest filing, from $2.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $13.1 million in Q2 2025 and bottomed at $2.1 million in Q4 2025.
• Historically, Operating Expenses has averaged $5.6 million across 5 years, with a median of $5.0 million in 2022.
• Annual changes were most pronounced in 2024 — Operating Expenses soared 86.98% — and 2025, when it sank 54.96%.
• Theriva Biologics' Operating Expenses stood at $7.3 million in 2022, then declined by 15.03% to $6.2 million in 2023, then dropped by 26.33% to $4.6 million in 2024, then tumbled by 54.96% to $2.1 million in 2025, then gained by 17.64% to $2.4 million in 2026.
• Business Quant data shows TOVX's Operating Expenses at $2.4 million in Q1 2026, $2.1 million in Q4 2025, and $4.4 million in Q3 2025.